Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUC-MSCs for High-risk HPV Infection
NCT06610773Phase 2Recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Mar 2024
- Primary completion
- Sep 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human papillomavirus infection comparing hUC-MSCs Group with Placebo Group (2 arms). Primary endpoints: Incidence rate of allergic reaction at 36 weeks and The 24 type HPV viral load at 36 weeks. Started Mar 2024; status: recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT06610773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06610773.